Latest news with #GATC
The Hindu
6 days ago
- Entertainment
- The Hindu
Girish and the Chronicles bring their hard rock power to Hyderabad
Mention Bengaluru-based Girish and the Chronicles (GATC) in a room full of rock fans and watch the mood shift — soaring vocals, powerful guitars, and memories of the band's blistering live sets take centre stage. For over a decade, the four-piece band has been a driving force in India's hard rock and melodic metal scene. Originally from Sikkim, GATC comprises Girish Pradhan (vocals), Nagen Mongranti (drums), Yogesh Pradhan (bass), and Suraz Karki (guitar). Having shared stages with rock royalty — Guns N' Roses, Skid Row, Nazareth, Alter Bridge, and Megadeth's Chris Adler during his India tour — GATC's resume reads like a metalhead's dream. But speak to Girish and the conversation returns to Sikkim, where it all began. 'My brother and I were discovering music on our own,' Girish recalls. 'We grew up in the cassette era, which forced us to really listen. Yogesh was playing around with guitars, and I started taking vocals seriously at around 14. Music was always around — our mum's a singer and most of our cousins played guitar.' That early exposure, thanks to cassettes and classic MTV, was formative. 'Shows would play everything from Iron Maiden and Bon Jovi to Lenny Kravitz and Metallica. Songs like Jaded, It's My Life, and Fly Away just blew our minds. Later we realised many of these bands were already legends from the '80s!' Girish credits their musical awakening to the rich, music-loving culture of the Northeast. 'We were lucky to grow up in it.' Their first band, Anarchy, formed when Girish was in Class 11 and Yogesh in Class 9. 'I was on vocals and rhythm guitar. Yogesh started out on drums. Our dad, Shyam Pradhan, who was a football commentator, was incredibly supportive,' Girish says. Their breakout moment was at a school show in 2004 that drew over 5,000 people. 'We were blown away,' said Girish. Now, over two decades later, GATC is set to perform in Hyderabad on May 31 at Hard Rock Café. 'It's not our first time in the city, but we're always excited to play. Every show feels new,' says Girish. Those early gigs were more than just performances — they were GATC's initiation into the world of concerts and crowd energy. Over the years, the band took every opportunity that came their way. Their commitment to rock 'n' roll often earned them the wrong kind of attention. 'There was a phase when people labelled us as 'boys with bad habits' just because we were in a rock band,' Girish recalls. 'It wasn't pleasant. But nothing is permanent, thankfully.' When asked what fuels his songwriting, Girish says it is deeply personal. 'I started writing from a young age, and my songs often reflect my own situations — what kind of year it's been, what's going on in my life or around me.' Was there ever a moment when the dream felt uncertain? 'Absolutely. I pursued nothing but music. I was in a band that didn't work out. Then I went solo and dropped out of engineering—without telling anyone. It was a risk. But I knew this was what I had to do.' That decision took him to Kathmandu, where he spent a transformative year immersed in the city's vibrant music scene. 'Kathmandu was my real college. I learnt everything I could about music there.' In 2009, he returned to Gangtok and recorded his first single, Angel, with his brother, who was home for the holidays while studying sound engineering. Around the same time, Girish's YouTube channel began gaining traction. 'YouTube became a turning point. It's how music lovers discovered us,' he says. 'Honestly, YouTube and Facebook were our passports to popularity.' The momentum continued. In 2010, GATC became the first band from the Northeast to be invited to a European music festival— Suncane Skale International Music Awards Festival in Montenegro, Europe. Two years later, in 2012, they spent a full year as the house band for a major club in Hong Kong. Their debut album released in 2014 — and now, their fourth album is slated for a September 2025 release. Girish And The Chronicles will be playing at Hard Rock Cafe, Hitec City, Hyderabad on May 31.
Yahoo
22-05-2025
- Business
- Yahoo
GATC Health Paper Quantifies AI-Driven Capital Efficiencies and Advances Human-Centered Drug Discovery
IRVINE, Calif., May 22, 2025 /PRNewswire/ -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, has published a new paper, AI in Drug Development: Advancing Capital Efficiency, Reducing Animal Testing, and Driving Precision Medicine. The paper details how advancements such as GATC's Multiomics Advanced Technology™ (MAT) platform are reshaping pharmaceutical development by improving speed, cost, and accuracy while reducing reliance on animal testing through human-relevant AI models. Ultimately, these technologies provide practical solutions to the industry's key challenges and promise to deliver better, safer treatments—faster—to patients. Highlights include: Validated, Highly Accurate Predictions: GATC Health's MAT was validated by University of California, Irvine, with predictions of sensitivity at 86% and specificity at 91%. Digital Twin Models: Models of human biological systems can test thousands of drug candidates in silico—achieving results 1,000x faster than conventional methods and at dramatically lower cost. Reduction in Animal Testing: The platform simulates human biology, enabling accurate predictions without animal studies and supporting regulatory shifts like the FDA Modernization Act. AI-driven methods could replace animal testing for up to 38.4 million animals annually. Public Health Impact: Accelerated drug development means faster access to new therapeutics, with the potential to save millions of years of human life. "This paper underscores our commitment to scientific and ethical progress in drug discovery," said Jayson Uffens, Chief Technology Officer at GATC Health. "By improving capital efficiency and reducing animal testing, we aim to advance both innovation and responsibility in the industry." Transforming Drug Development EconomicsTraditional drug development can cost up to $2.4 billion and take 12 years per drug. GATC's MAT platform streamlines discovery and preclinical phases, enabling companies to avoid costly investments in unlikely candidates and reinvest savings into further research. As noted in the paper, AI-driven preclinical assessments can cut animal use, increase human relevance, and reduce expenses by up to 90%. This streamlined process can shorten time to Investigational New Drug (IND) filing from over a decade to under two years. Advancing Ethical, Cost-Effective SolutionsConventional animal models often fail to predict human outcomes and raise ethical issues. GATC's AI-driven approach reduces animal use by up to 70% per drug candidate, aligning with global moves toward non-animal testing. Virtual toxicology datasets and digital twins replace animal models with more accurate and humane alternatives. Aligning with Regulatory TrendsThe paper details how AI technologies support evolving regulatory requirements, enabling faster, more precise, and ethically responsible drug development. GATC Health invites industry stakeholders to review the full paper and participate in the ongoing dialogue about the future of drug discovery. Visit GATC Health's Resources page to download the full paper. About GATC HealthGATC Health Corp. is a technology company transforming drug discovery and development through its AI-driven platform and approach. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry's billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and derisk drug pipelines by predicting efficacy, safety, and off-target more information, visit View original content to download multimedia: SOURCE GATC Health Corp
Yahoo
14-05-2025
- Business
- Yahoo
Dyno Therapeutics Announces Inaugural 2025 Genetic Agency Technology Conference and Launch of Dyno Frontiers Program to Accelerate Progress in Patient-Empowering Gene Therapies
The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates across the gene therapy community to foster collaboration and align efforts towards solving unmet patient needs. The new Dyno Frontiers Program offers therapeutic developers access to Dyno's gene delivery technology and scientific expertise towards demonstrating the transformative therapeutic potential of innovative genetic payloads. These initiatives reinforce Dyno's commitment to enabling genetic agency by empowering patients to take action and improve their health with safe, effective and widely accessible genetic technologies. WATERTOWN, Mass., May 14, 2025--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying AI to enable safe and effective in vivo delivery of genetic medicines, today announced two new initiatives designed to accelerate progress across the gene therapy field: the inaugural Genetic Agency Technology Conference (GATC) and the Dyno Frontiers Program for innovative therapeutic developers. Details were shared during the company's Scientific Symposium at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. "At Dyno, we believe that building the next generation of therapies will require not just new technical innovation, but also collaboration between many stakeholders and a focused effort to thoroughly solve present bottlenecks," said Eric Kelsic, Ph.D., CEO and Cofounder of Dyno. "These two new initiatives reflect Dyno's commitment to maximizing our positive impact on patients. We achieve this by partnering and by deepening relationships within a community of gene therapy developers, technical experts and patients, along with their families and patient advocates – all united by the common goal of enabling patients to improve their health with safe and effective genetic medicines." The Genetic Agency Technology Conference Dyno's GATC event is scheduled to take place in Boston, Massachusetts on November 11th, 2025. This one-day interactive gathering will convene leaders from across the gene therapy ecosystem—including technical experts, therapeutic developers, patients, their families and patient advocates—to strengthen a community working to develop cutting-edge technologies and drive progress toward solving unmet patient needs. With GATC, Dyno aims to spark collaboration around the shared goal of genetic agency: giving patients the ability to improve their health at a genetic level through access to next‑generation gene technologies that are safe, effective and widely accessible. "When developing a new technology, the most important thing is to make something people want. GATC will bring therapeutic developers working at the frontiers of science and technology together with those who care the most about these transformative treatments: patients, their families and patient advocacy organizations. As we team up to overcome the extraordinary challenges required to develop groundbreaking new medicines, we should also recognize the amazing progress that is being made across fields, and look ahead with optimism to a better future for patients that we can build, when leaders across science, technology, and patient advocacy work together," Kelsic explains. "By bringing the developers and users of these technologies together, GATC will catalyze collaboration, helping uncover the true nature of present challenges, and generating unexpected insights that will accelerate progress to realize the potential of what genetic medicine can deliver for patients." Interested participants can sign up for updates or request an invitation at Further details about the conference will be announced in the coming months. The Dyno Frontiers Program Building on Dyno's successful partnerships with leading gene therapy companies, the Dyno Frontiers Program focuses on assisting select gene therapy developers looking to demonstrate the transformative therapeutic potential of their innovative genetic payloads. The program provides technological and scientific support for developers to initiate non-human primate (NHP) studies with clinic-ready genetic payloads for eye, muscle, or central nervous system indications. Participants in the Frontiers Program will: Gain access to Dyno's leading-edge AAV capsid delivery vectors to demonstrate the in vivo effectiveness of their innovative clinic-ready genetic payloads in eye, muscle, or central nervous system indications. Receive scientific advice from Dyno on capsid selection, NHP study design, vector manufacturing, and performance quantification. Collaborate with Dyno to measure capsid performance across distinct payload modalities. "As genetic technologies advance and diversify, gene therapy developers increasingly need high-performance delivery vectors to realize the therapeutic potential of their innovative payload strategies," Kelsic continued. "We're excited to offer this first-of-its-kind opportunity for innovative gene therapy developers to demonstrate the in vivo effectiveness of their genetic payloads, bringing these transformative drug candidates one critical step closer to the patients who need them most." Eligible therapeutic developers seeking to demonstrate the therapeutic potential of their innovative clinic-ready genetic payloads are invited to participate at About Dyno Therapeutics Dyno Therapeutics' mission is to build high-performance genetic technologies that transform patient lives. Dyno is creating better technologies for gene delivery and sequence design to increase "Genetic Agency"—the capacity for patients to take action and improve their health at a genetic level—enabling individuals to live the life they choose through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput in vivo experimentation, Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including strategic collaborations with leading gene therapy developers Astellas, Roche and Sarepta, and with technology companies including NVIDIA. Visit for more information. Note: The Dyno Frontiers Program is a research initiative and does not imply clinical validation, endorsement, or regulatory approval. View source version on Contacts Media Contact:Thermal for Dyno Therapeuticsdynotx@ Sign in to access your portfolio
Business Wire
14-05-2025
- Business
- Business Wire
Dyno Therapeutics Announces Inaugural 2025 Genetic Agency Technology Conference and Launch of Dyno Frontiers Program to Accelerate Progress in Patient-Empowering Gene Therapies
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dyno Therapeutics, Inc., a genetic technologies company applying AI to enable safe and effective in vivo delivery of genetic medicines, today announced two new initiatives designed to accelerate progress across the gene therapy field: the inaugural Genetic Agency Technology Conference (GATC) and the Dyno Frontiers Program for innovative therapeutic developers. Details were shared during the company's Scientific Symposium at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. 'At Dyno, we believe that building the next generation of therapies will require not just new technical innovation, but also collaboration between many stakeholders and a focused effort to thoroughly solve present bottlenecks,' said Eric Kelsic, Ph.D., CEO and Cofounder of Dyno. 'These two new initiatives reflect Dyno's commitment to maximizing our positive impact on patients. We achieve this by partnering and by deepening relationships within a community of gene therapy developers, technical experts and patients, along with their families and patient advocates – all united by the common goal of enabling patients to improve their health with safe and effective genetic medicines.' The Genetic Agency Technology Conference Dyno's GATC event is scheduled to take place in Boston, Massachusetts on November 11th, 2025. This one-day interactive gathering will convene leaders from across the gene therapy ecosystem—including technical experts, therapeutic developers, patients, their families and patient advocates—to strengthen a community working to develop cutting-edge technologies and drive progress toward solving unmet patient needs. With GATC, Dyno aims to spark collaboration around the shared goal of genetic agency: giving patients the ability to improve their health at a genetic level through access to next‑generation gene technologies that are safe, effective and widely accessible. 'When developing a new technology, the most important thing is to make something people want. GATC will bring therapeutic developers working at the frontiers of science and technology together with those who care the most about these transformative treatments: patients, their families and patient advocacy organizations. As we team up to overcome the extraordinary challenges required to develop groundbreaking new medicines, we should also recognize the amazing progress that is being made across fields, and look ahead with optimism to a better future for patients that we can build, when leaders across science, technology, and patient advocacy work together,' Kelsic explains. 'By bringing the developers and users of these technologies together, GATC will catalyze collaboration, helping uncover the true nature of present challenges, and generating unexpected insights that will accelerate progress to realize the potential of what genetic medicine can deliver for patients.' Interested participants can sign up for updates or request an invitation at Further details about the conference will be announced in the coming months. The Dyno Frontiers Program Building on Dyno's successful partnerships with leading gene therapy companies, the Dyno Frontiers Program focuses on assisting select gene therapy developers looking to demonstrate the transformative therapeutic potential of their innovative genetic payloads. The program provides technological and scientific support for developers to initiate non-human primate (NHP) studies with clinic-ready genetic payloads for eye, muscle, or central nervous system indications. Participants in the Frontiers Program will: Gain access to Dyno's leading-edge AAV capsid delivery vectors to demonstrate the in vivo effectiveness of their innovative clinic-ready genetic payloads in eye, muscle, or central nervous system indications. Receive scientific advice from Dyno on capsid selection, NHP study design, vector manufacturing, and performance quantification. Collaborate with Dyno to measure capsid performance across distinct payload modalities. 'As genetic technologies advance and diversify, gene therapy developers increasingly need high-performance delivery vectors to realize the therapeutic potential of their innovative payload strategies,' Kelsic continued. 'We're excited to offer this first-of-its-kind opportunity for innovative gene therapy developers to demonstrate the in vivo effectiveness of their genetic payloads, bringing these transformative drug candidates one critical step closer to the patients who need them most.' Eligible therapeutic developers seeking to demonstrate the therapeutic potential of their innovative clinic-ready genetic payloads are invited to participate at About Dyno Therapeutics Dyno Therapeutics' mission is to build high-performance genetic technologies that transform patient lives. Dyno is creating better technologies for gene delivery and sequence design to increase 'Genetic Agency'—the capacity for patients to take action and improve their health at a genetic level—enabling individuals to live the life they choose through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput in vivo experimentation, Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including strategic collaborations with leading gene therapy developers Astellas, Roche and Sarepta, and with technology companies including NVIDIA. Visit for more information. Note: The Dyno Frontiers Program is a research initiative and does not imply clinical validation, endorsement, or regulatory approval.
Yahoo
28-01-2025
- Business
- Yahoo
West Virginia University and GATC Health Partner to Launch Strategic Program to Accelerate Academic Research into Market-Ready Therapies
The innovative program harnesses GATC's AI-powered platform to rapidly de-risk and optimize drug discovery and development, accelerating the transition to clinical trials. MORGANTOWN, Jan. 28, 2025 /PRNewswire/ -- West Virginia University (WVU), one of the top public research institutions in the nation, has formed a strategic partnership with GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery. The collaborative agreement facilitates the combination of WVU's early-stage drug research and GATC's AI drug discovery platform to accelerate commercialization and create de-risked bio-tech investment opportunities. The program aims to de-risk and accelerate the commercialization of groundbreaking research conducted at WVU. Utilizing GATC Health's Multiomics Advanced Technology™ (MAT) AI, which simulates complex systems biology with approximately 90% accuracy, the program empowers researchers to simulate billions of biological interactions, enabling rapid, accurate target discovery, drug identification, and testing at the earliest stages of drug development. By predicting safety, efficacy, and off-target effects, GATC's platform reduces the risk, time, and cost of traditional drug discovery while simulating clinical trial outcomes before laboratory work begins. GATC's technology has contributed to significant discoveries in addiction, PTSD, diabetes, obesity, glioblastoma, and cognitive decline. The partnership not only advances academic research but also creates compelling investment opportunities by significantly reducing the risks traditionally associated with biopharma ventures. By leveraging GATC Health's AI, the program identifies high-potential projects early in the drug development process. This precision enables faster decision-making while de-risking university research as it progresses toward pre-clinical work, IND-enabling studies, and clinical trials. As the exclusive AI partner with Lloyd's of London syndicate Medical & Commercial International and in partnership with Acrisure Re Corporate Advisory & Solutions, the international financing and consulting firm responsible for program sales and distribution, GATC is supporting the underwriting of the first insurance-backed financial program to fund clinical trials, offering a secure and innovative funding source for joint ventures stemming from WVU and GATC collaborations. "This partnership highlights West Virginia University's dedication to driving innovation and transforming lives through groundbreaking research," said Dr. Clay Marsh, Chancellor & Executive Dean for Health Sciences at West Virginia University. "By joining forces with GATC Health and utilizing their cutting-edge AI technology, we are empowering our researchers to accelerate the path from academic discovery to life-changing therapies, ensuring WVU remains at the forefront of addressing critical healthcare challenges and delivering meaningful outcomes that benefit patients in West Virginia and across the globe." Traditional drug discovery and development is a notoriously risky, expensive, and time-consuming process, often requiring over a decade and billions of dollars to bring a single therapy to market. The high failure rate—nearly 90% of drug candidates fail during clinical trials—stems from challenges such as inaccurate target identification, unforeseen toxicity, poor efficacy, and lengthy preclinical and clinical trial processes. By applying GATC Health's AI across these critical stages, drug discovery is becoming faster, more efficient, and more likely to succeed. "We are thrilled to partner with WVU and launch our University Research Accelerator Program," said Tyrone Lam, Chief Business Officer of GATC Health Corp. "This collaboration highlights our commitment to empowering academic institutions with cutting-edge AI tools that bridge the gap between research and commercialization, enabling faster delivery of life-changing therapies." By focusing on high-probability projects and leveraging GATC's "fast-fail" AI analysis, WVU will not only enhance its research capacity but also generate revenue much earlier in the discovery process. This innovative approach establishes WVU as a leader in AI-driven research commercialization. GATC West Virginia, a subsidiary of GATC Health, is enhancing its AI-powered lab operations within the WVU Innovation Building, strategically located near West Virginia University's campus. The state-of-the-art lab facilitates rapid iteration between GATC's MAT AI and traditional lab experiments. Currently, it is focused on synthesizing drug compounds, a critical step in advancing preclinical testing for innovative treatments targeting conditions such as opioid use disorder, polysubstance use disorder, post-traumatic stress disorder, anxiety, diabetes, glioblastoma, Alzheimer's and more. To support this growth, GATC West Virginia is expanding its preclinical capabilities by hiring additional scientists this year, reinforcing its commitment to innovation and scientific excellence. About West Virginia UniversityWest Virginia University, located in Morgantown, WV, is a leading public research institution dedicated to creating solutions that address the challenges of today and tomorrow. Through its world-class faculty and innovative research initiatives, WVU is driving advancements across a wide range of disciplines. About GATC Health CorpGATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry's billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects. For more information, visit View original content to download multimedia: SOURCE GATC Health Corp
